INHIBRX
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.
INHIBRX
Industry:
Biotechnology Therapeutics
Founded:
2010-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.inhibrx.com
Total Employee:
51+
Status:
Active
Total Funding:
69.59 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Employees Featured
Founder
Stock Details
Investors List
RA Capital Management
RA Capital Management investment in Convertible Note - Inhibrx
Alexandria Venture
Alexandria Venture investment in Convertible Note - Inhibrx
Lilly Asia Ventures
Lilly Asia Ventures investment in Convertible Note - Inhibrx
ArrowMark Partners
ArrowMark Partners investment in Convertible Note - Inhibrx
WuXi Biologics
WuXi Biologics investment in Convertible Note - Inhibrx
Viking Global Investors
Viking Global Investors investment in Convertible Note - Inhibrx
CARB-X
CARB-X investment in Grant - Inhibrx
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Inhibrx
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-28 | Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors |
Official Site Inspections
http://www.inhibrx.com Semrush global rank: 2.76 M Semrush visits lastest month: 5.86 K
- Host name: 199.16.173.123
- IP address: 199.16.173.123
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Inhibrx"
Inhibrx - Crunchbase Company Profile & Funding
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.See details»
Investors | Inhibrx Bioscience Inc. | Adaptable
Inhibrx, inc. - Report of Organizational Actions Affecting Basis of Securities On May 29, 2024, Inhibrx, inc. (the “company”) distributed 92% of the issued and outstanding shares of the common stock in its subsidiary, Inhibrx biosciences, …See details»
Our Team | Inhibrx | Meet our experts in biotherapeutics.
With proven track records in biotherapeutics and a commitment to synergistic teamwork, we find that our people are as dynamic as our technology.See details»
Inhibrx - Funding, Financials, Valuation & Investors - Crunchbase
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.See details»
Inhibrx - Contacts, Employees, Board Members, Advisors & Alumni
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.See details»
Inhibrx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
About Inhibrx Biosciences, Inc. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates.See details»
Inhibrx Biosciences, Inc. - LinkedIn
Inhibrx Biosciences, Inc. | 5,720 followers on LinkedIn. Innovation Focused Outcomes Driven | At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening ...See details»
Inhibrx | Investors - Investors
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare …See details»
InhibRx Company Profile - Office Locations, Competitors ... - Craft
InhibRx has 5 employees at their 1 location and $1.8 m in annual revenue in FY 2023. See insights on InhibRx including office locations, competitors, revenue, financials, executives, …See details»
Sanofi completes acquisition of Inhibrx, Inc.
May 30, 2024 Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, …See details»
Inhibrx: The Biotech Spinoff Poised For Big Gains
Sep 15, 2024 Discover why Inhibrx is a hidden gem in biotech, poised for major growth with innovative treatments. For more investment insights, reach out or explore my company todaySee details»
Who We Are | Inhibrx | Fresh perspective. Validated targets.
At Inhibrx you’ll not only find a cohort of established, focused, and meticulous scientists, but also a close-knit, creative, and adventurous team. With a shared vision and intrinsic motivation to get …See details»
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
6 days ago Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the …See details»
Inhibrx Biosciences - Overview, News & Similar companies
Nov 4, 2024 View Inhibrx Biosciences (www.inhibrx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best ...
Jan 23, 2006 Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi’s portfolio growth …See details»
INBRX-106 | Inhibrx | Utilizing a member of the TNFRSF.
OX40 is a member of the TNFRSF (TNF receptor superfamily). We believe INBRX-106, our hexavalent OX40 agonist, can outperform bivalent agonists.See details»
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate …
Jan 23, 2024 Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that …See details»
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
6 days ago SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and …See details»
Inhibrx (INBX) Earnings Date and Reports 2025 - MarketBeat
3 days ago When is Inhibrx's next earnings announcement? View the latest INBX earnings date, analysts forecasts, earnings history, and conference call transcripts.See details»
Inhibrx, Inc.
It is the policy of Inhibrx, Inc. (the “Corporation”) that the Nominating and Corporate Governance Committee (the “Committee”) of the Board of Directors (the “Board”) consider …See details»